News

The Foundation’s funding will support Owlstone Medical’s development of a breath test to help doctors diagnose and monitor Pseudomonas aeruginosa infections in people with cystic fibrosis.

New co-chairs represent the wide range of experiences in the CF community.

Notice and comment process provides an invaluable platform for patients to share real world experiences, concerns, and implications of proposed rules issued by HHS.  

Volunteers shared personal stories about life with CF while urging members of Congress to protect patients and progress.

Protecting research is vital to ensuring people with CF can lead long, fulfilling lives.

A new CFTR modulator treatment called Alyftrek has been approved for people with CF ages 6 and older who have CFTR mutations that are eligible for Trikafta, as well as 31 other rare mutations that have not been approved previously for any other CFTR modulator.

The U.S. Food and Drug Administration (FDA) today approved the expansion of Trikafta (elexacaftor/tezacaftor/ivacaftor) to people with cystic fibrosis ages 2 and older who have at least one of 94 rare mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Results underscore the widespread challenges faced by individuals with cystic fibrosis in managing health care expenses.

The Cystic Fibrosis Foundation is funding the development of a gene editing therapy that is designed to use ReCode’s tissue-specific delivery vehicle to transport gene editing cargo to the lung cells in people with cystic fibrosis.

Through grants, advocacy, and the development of a consensus guideline, the Cystic Fibrosis Foundation continues to advance its Newborn Screening Initiative, pushing for better newborn screening practices to curb delayed diagnoses and further progress health equity.